Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Swiss biotech NLS...

    Swiss biotech NLS Pharmas ADHD drug succeeds in mid-stage study

    Written by Ruby Khatun Khatun Published On 2017-06-01T12:23:53+05:30  |  Updated On 1 Jun 2017 12:23 PM IST
    Swiss biotech NLS Pharmas ADHD drug succeeds in mid-stage study
    Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a late-stage trial.

    ADHD is a chronic condition characterized by hyperactivity, impulsive behavior and a difficulty in sustaining focus.


    There are currently two types of approved medications used to manage symptoms: stimulants and non-stimulants.


    NLS' drug, mazindol, is a non-stimulant, but trial data showed it could be as effective as a stimulant.


    Stimulants are typically more effective than other drugs and are believed to elevate levels of dopamine — a neurotransmitter associated with motivation and attention. But they carry a risk of abuse, may be poorly tolerated by patients, and even be fatal in rare cases.


    Shire Plc's Adderall and Vyvanse are examples of stimulants that belong to a class of drugs called amphetamines — the same class that includes crystal meth and ecstasy. Other stimulants include Concerta and Ritalin.


    Non-stimulants, including Eli Lilly's Strattera, work slower than stimulants, but have a cleaner side-effect profile.


    The "holy grail" of ADHD treatments is to develop a non-stimulant medicine that works as well as a stimulant, Gregory Mattingly, an NLS study investigator said.


    Mazindol does not have the same magnitude of effect on dopamine as stimulants do. As a result, it is categorized as a less-restrictive, Schedule IV drug under U.S. regulations, Mattingly said.


    Standard stimulants are considered Schedule II drugs, which invite more scrutiny due to their potential for abuse. Patient access can be inconvenient as these drugs require monthly refills and written prescriptions.


    In NLS' 85-patient trial, more than half the patients who received mazindol experienced an over 50 percent reduction in ADHD symptoms, compared with 15.8 percent of patients on a placebo.


    Many studies, especially those testing non-stimulant ADHD drugs, have used a 25-30 percent threshold for reduction in symptoms, Mattingly said.


    Mazindol was previously approved for the short-term treatment of obesity, but has since been withdrawn for reasons unrelated to safety or efficacy.


    Up to 11 percent of American children have ADHD, and more than half continue to suffer from it as adults, according to recent figures.


    Two-thirds of children diagnosed are receiving treatment, but up to 80 percent of adults are not, making that market ripe for growth, Mattingly said.


    Other ADHD drug developers include Neos Therapeutics Inc, Alcobra Ltd and Aevi Genomic Medicine Inc.


    (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

    ADHDamphetaminesAttention deficient hyperactivity disorderbiotechConcertadopamineEli LillyGregory MattinglymazindolNLS PharmaNLS Pharma AGRitalinStimulantsStratteraSwiss biotech
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok